Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyDavid S. Ettinger, Miranda Hughes, Christine M. Lovly et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 1.4k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersJeffrey A. Engelman, Kwok‐Kin Wong, Liang Chen et al.|Nature Medicine|2008Cited by 1.3k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021David S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020David S. Ettinger, Douglas E. Wood, Charu Aggarwal et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 1k
Non–Small Cell Lung Cancer, Version 4.2024Gregory J. Riely, Lisa Hang, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 746